LLY

1,001.71

+1.15%↑

JNJ

228.39

+1.37%↑

ABBV

206.3

-0.96%↓

UNH

398.54

+2.15%↑

AZN

185.57

+0.3%↑

LLY

1,001.71

+1.15%↑

JNJ

228.39

+1.37%↑

ABBV

206.3

-0.96%↓

UNH

398.54

+2.15%↑

AZN

185.57

+0.3%↑

LLY

1,001.71

+1.15%↑

JNJ

228.39

+1.37%↑

ABBV

206.3

-0.96%↓

UNH

398.54

+2.15%↑

AZN

185.57

+0.3%↑

LLY

1,001.71

+1.15%↑

JNJ

228.39

+1.37%↑

ABBV

206.3

-0.96%↓

UNH

398.54

+2.15%↑

AZN

185.57

+0.3%↑

LLY

1,001.71

+1.15%↑

JNJ

228.39

+1.37%↑

ABBV

206.3

-0.96%↓

UNH

398.54

+2.15%↑

AZN

185.57

+0.3%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc
Search

Rhythm Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

96.22 7.32

Силна покупка

Обновена цена 13.05.2026 г., 16:45 ч. UTC

КупиПродай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

89.27

Максимум

96.9

Ключови измерители

By Trading Economics

Приходи

-8.1M

-56M

Продажби

2.9M

60M

EPS

-0.83

Марж на печалбата

-92.559

Служители

414

EBITDA

-9.7M

-52M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+49.79% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

124M

6B

Предишно отваряне

88.9

Предишно затваряне

96.22

Настроения в новините

By Acuity

61%

39%

293 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.05.2026 г., 22:50 ч. UTC

Печалби

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

DJ

Прочетени

12.05.2026 г., 22:49 ч. UTC

Печалби

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

DJ

Прочетени

12.05.2026 г., 22:32 ч. UTC

Печалби

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

DJ

Прочетени

12.05.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

DJ

Прочетени

12.05.2026 г., 22:57 ч. UTC

Пазарно говорене
Печалби

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

DJ

Прочетени

12.05.2026 г., 22:26 ч. UTC

Печалби

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

DJ

Прочетени

12.05.2026 г., 22:25 ч. UTC

Печалби

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

DJ

Прочетени

12.05.2026 г., 22:25 ч. UTC

Печалби

Aristocrat Leisure Interim Dividend A$0.50/Security

DJ

Прочетени

12.05.2026 г., 22:24 ч. UTC

Печалби

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

DJ

Прочетени

12.05.2026 г., 22:23 ч. UTC

Печалби

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

DJ

Прочетени

12.05.2026 г., 22:23 ч. UTC

Печалби

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

DJ

Прочетени

12.05.2026 г., 22:19 ч. UTC

Печалби

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:14 ч. UTC

Печалби

CBA: Business Lending Continued to Grow Above System>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:14 ч. UTC

Печалби

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:13 ч. UTC

Печалби

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:12 ч. UTC

Печалби

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:12 ч. UTC

Печалби

CBA 3Q New Home Loan Funding A$45B>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:11 ч. UTC

Печалби

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

DJ

Прочетени

12.05.2026 г., 22:11 ч. UTC

Печалби

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:10 ч. UTC

Печалби

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:09 ч. UTC

Печалби

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:09 ч. UTC

Печалби

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

DJ

Прочетени

12.05.2026 г., 22:08 ч. UTC

Печалби

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:07 ч. UTC

Печалби

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:06 ч. UTC

Печалби

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:06 ч. UTC

Печалби

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:05 ч. UTC

Печалби

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

DJ

Прочетени

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

DJ

Прочетени

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

DJ

Прочетени

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

DJ

Прочетени

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

49.79% нагоре

12-месечна прогноза

Среден 136.77 USD  49.79%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

14

Купи

0

Задържане

0

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Средносрочен план

Bullish Evidence

All events are bullish.

Дългосрочен план

Bullish Evidence

Recent bullish events outweigh bearish events.

Настроение

By Acuity

293 / 346 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Други акции от сектора

LLY

Eli Lilly and Co.

1,001.71

↑ +1.15%

JNJ

Johnson and Johnson

228.39

↑ +1.37%

ABBV

AbbVie Inc

206.3

↓-0.96%

UNH

UnitedHealth Group Inc

398.54

↑ +2.15%

AZN

AstraZeneca PLC

185.57

↑ +0.3%
help-icon Live chat